


The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:


1. (Cancelled) A pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of general formula (I)



wherein R_1 and R_2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

2. (Cancelled) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R_1 and R_2 are a straight-chain C_{1-14} alkyl residue or a C_{3-14} cycloalkyl residue each.
3. (Cancelled) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R_1 and R_2 are CH_3CH_2 each.
4. (Cancelled) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.

5. (Cancelled) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deoxyspergualine, OKT3 and azathioprine.
6. (Cancelled) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or further cytostatic agents.
7. (Cancelled) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer agent.
8. (Cancelled) The pharmaceutical preparation according to claim 1, further comprising a pharmaceutically compatible inert carrier or a diluent.
9. (Cancelled) Use of a pharmaceutical preparation according to claim 1 for treating a cancerous disease.
10. (Cancelled) Use according to claim 9, wherein the cancerous disease is the parvocellular bronchial carcinoma or colorectal carcinoma.
11. (Cancelled) A process for the production of a pharmaceutical preparation according to claim 8, characterized in that the compound according to formula (I) is mixed with the pharmaceutically compatible inert carrier or diluent.
12. (Previously Amended) A method of treating a cancerous disease sensitive to a compound of formula (I)



wherein R_1 and R_2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents,

comprising administering a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula (I) to a human being or a mammal in need thereof in an amount effective to treat said cancerous disease.

13. (Previously Added) The method of claim 12, wherein said cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.
14. (Cancelled) The pharmaceutical preparation according to claim 6, wherein the further cytostatic agent is cisplatin, methotrexate, aminopterin, dacarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, or mitomycin C.
15. (Previously Amended) The method according to claim 12, wherein said cancerous disease is selected from testicular tumor, ovarian carcinoma, bladder carcinoma, colonic carcinoma, prostatic carcinoma, parvocellular and non-parvocellular bronchial carcinoma, carcinoma of the cephalic and cervical parts, carcinoma of the thoracic and abdominal regions, cervical and endometrial carcinoma, sarcoma, melanoma and leukemia.
16. (Previously Amended) The method of claim 12, wherein in the compound of formula (I) R_1 and R_2 are each independently a straight-chain C_{1-14} alkyl residue or a C_{3-14} cycloalkyl residue.
17. (Previously Added) The method of claim 12, wherein in the compound of formula (I) R_1 and R_2 are each CH_3CH_2 .

18. (Previously Added) The method of claim 12, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.
19. (Currently Amended) The method of claim 12, wherein said ~~compound~~ pharmaceutical preparation further comprises a pharmaceutically compatible inert carrier or a diluent.